Select a Region North America


Imtiaz Samjoo

Senior Director, Value & Evidence


Health Economic Marketing, Health Economic Research, HEOR, Peer-Reviewed Publications, Research & Insights, RWE

As Senior Director of the Value & Evidence team at EVERSANA, Imtiaz leads evidence synthesis projects that support global HEOR initiatives involving systematic literature reviews, indirect treatment comparisons, and health economic modeling,  to support reimbursement and market
access for pharmaceuticals.

Imtiaz Samjoo is the Senior Director of Evidence Synthesis at EVERSANA. Imtiaz has more than 10 years of academic research and scientific writing experience, with expertise in molecular and clinical research and a specialty in anatomy, biochemistry, metabolism, and physiology. He has authored over 20 peer-reviewed scientific publications. His academic training includes an Honours BSc (Biology) from McMaster/Leeds University, an MSc in Physiology and Pharmacology (McMaster University) and a Ph.D. in Cell Biology and Metabolism (McMaster University).

At EVERSANA, Imtiaz specializes in the conduct and critical appraisal of evidence synthesis activities including traditional and network meta-analysis, advanced ITCs such as MAICs and STCs, ITC feasibility assessments, systematic and targeted literature reviews, developing objection handlers, gap and landscape assessments, product value communication tools, peer-reviewed manuscripts, value messages, slide decks, and conference abstracts and posters. Additionally, Imtiaz is involved in the development and implementation of tools that demonstrate the health economic value of pharmaceuticals and medical devices. These include cost-effectiveness, cost-consequence, and budget impact analysis models and sales force tools. He has worked in several therapeutic areas, including cardiovascular disease, diabetes, gastroenterology, mental illness, neurology, and oncology.

Articles by Imtiaz Samjoo

Uncovering Health Disparities: Exploring Social Determinants of Metastatic Prostate Cancer Survival

Author(s): Imtiaz A. Samjoo, MSc, PhD; Emily Rosta, MSc; Austin Lansing, MSc; Alexandra Hall, MPH Despite recent advancements in metastatic prostate cancer (mPC) treatment, prevention and care, progress has not equally manifested in all population groups. Though some recent reports suggest similar outcomes across races, there continue to be reports of racial disparity in disease incidence and access to care. In a pair of interconnected articles, Stephen J. Freedland, MD, the team at Pfizer Inc. (Alexander Niyazov, Jonathan L. Nazari, and Bhakti Arondekar), and the Value & Evidence team at EVERSANA (Imtiaz A. Samjoo, Emily Rosta, Austin Lansing, Alexandra Hall, Manvir Rai, Kerise Clarke, Amrita Debnath, Evelyn Worthington, and Joanna Bielecki) […]

Eight Key Strategic Considerations When Launching a Global Indirect Treatment Comparison Program for New Products

Indirect treatment comparisons (ITCs) refer to a comparison of different healthcare interventions using data from separate studies, in contrast to a direct comparison within randomized controlled trials (RCTs). Indirect treatment comparisons are often used because of a lack of, or insufficient, evidence from head-to-head comparative trials. Indirect treatment comparisons have become valuable in evidence-based healthcare decision-making in disease prevention, diagnosis and treatment, and in other aspects of health. For example, clinicians, policymakers, and healthcare technology assessment (HTA) agencies worldwide often make decisions related to treatment in a given therapeutic area – they need to evaluate how a product’s clinical effects compare with already available treatment options for the indication in […]

Interested in scheduling a meeting or speaking event?